In France, manufacturers of innovative drugs are required to submit cost-effectiveness analysis and, in some cases, budget impact analysis, which the French Economic and Public Health Committee (CEESP) at the French Health Authority (HAS), use to deliver an economic opinion to the country’s pricing committee. Since 2013, these opinions have fundamentally evolved, and more recently, the methodological framework for the cost-effectiveness analysis at the HAS was updated, with major changes.
Having a good understanding of these changes and their impact is critical to prepare a high-quality submission file and can increase the likelihood of a timely, and successful positive opinion from the CEESP.
Join us to learn about the process leading to an economic opinion, the impact of the July 2020 methodological guidance, and how to choose the best methodology and effectively present it. We will focus on cost-effectiveness analysis for medicinal products and provide insights on:
- The key points of the choice of comparators
- The new guidelines for economic evaluation at the HAS, published in July 2020
- Recent CEESP economic opinions, based on a review between 2014 and 2020